GT Biopharma (GTBP)

GT Biopharma (GTBP) Stock Price & Analysis


GTBP Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.18 - $1.83
Previous Close$0.24
Average Volume (3M)126.61K
Market Cap
Enterprise Value-$8.24M
Total Cash (Recent Filing)$17.97M
Total Debt (Recent Filing)$120.00K
Price to Earnings (P/E)-0.8
Mar 27, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding41,418,999
10 Day Avg. Volume142,144
30 Day Avg. Volume126,615
Standard Deviation0.33
Financial Highlights & Ratios
Price to Book (P/B)0.82
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio2402.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.65
Price Target Upside1999.96% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1



Ownership Overview

3.24% Mutual Funds
3.17% Other Institutional Investors
93.59% Public Companies and
Individual Investors


What was GT Biopharma’s price range in the past 12 months?
GT Biopharma lowest stock price was $0.18 and its highest was $1.83 in the past 12 months.
    What is GT Biopharma’s market cap?
    Currently, no data Available
    When is GT Biopharma’s upcoming earnings report date?
    GT Biopharma’s upcoming earnings report date is Mar 27, 2024 which is in 111 days.
      How were GT Biopharma’s earnings last quarter?
      GT Biopharma released its earnings results on Nov 01, 2023. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.085 by $0.025.
        Is GT Biopharma overvalued?
        According to Wall Street analysts GT Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does GT Biopharma pay dividends?
          GT Biopharma does not currently pay dividends.
          What is GT Biopharma’s EPS estimate?
          GT Biopharma’s EPS estimate is -$0.09.
            How many shares outstanding does GT Biopharma have?
            GT Biopharma has 41,419,000 shares outstanding.
              What happened to GT Biopharma’s price movement after its last earnings report?
              GT Biopharma reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.085. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of GT Biopharma?
                Currently, no hedge funds are holding shares in GTBP


                Company Description

                GT Biopharma

                GT Biopharma, Inc. is engages in the development and commercialization of novel immuno-oncology products. Its products include OXS-1550, OXS-1650, OXS-3550, OXS-4550, OXS-1750, OXS-1950, and OXS-2050. The company was founded in 1965 and is headquartered in Westlake Village, CA.


                Top 5 ETFs holding GTBP

                Market Value
                Smart Score
                Vanguard Total Stock Market ETF
                Up to five ETFs with an Outperform Smart Score that hold GTBP. The ETFs are listed according to market value of GTBP within the ETF

                Forecast EPS vs Actual EPS

                Similar Stocks
                Price & Change
                ADMA Biologics
                Agios Pharma

                Popular Stocks

                What's Included in PREMIUM?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis